Cansino Historical Cash Flow

688185 Stock   61.23  0.13  0.21%   
Analysis of Cansino Biologics cash flow over time is an excellent tool to project Cansino Biologics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Borrowings of 1.5 B or Begin Period Cash Flow of 2.1 B as it is a great indicator of Cansino Biologics ability to facilitate future growth, repay debt on time or pay out dividends.
 
Covid
Financial Statement Analysis is much more than just reviewing and examining Cansino Biologics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cansino Biologics is a good buy for the upcoming year.
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cansino Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Cansino Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Cansino balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Cansino's non-liquid assets can be easily converted into cash.

Cansino Biologics Cash Flow Chart

At present, Cansino Biologics' Investments are projected to increase significantly based on the last few years of reporting. The current year's Net Borrowings is expected to grow to about 1.5 B, whereas Change To Inventory is forecasted to decline to (225.1 M).

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Dividends Paid

The total amount of dividends that a company has paid out to its shareholders over a specific period.

Capital Expenditures

Capital Expenditures are funds used by Cansino Biologics to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Cansino Biologics operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.
Most accounts from Cansino Biologics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Cansino Biologics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cansino Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.
At present, Cansino Biologics' Investments are projected to increase significantly based on the last few years of reporting. The current year's Net Borrowings is expected to grow to about 1.5 B, whereas Change To Inventory is forecasted to decline to (225.1 M).
 2021 2022 2023 2024 (projected)
Capital Expenditures1.2B1.1B659.7M574.7M
Dividends Paid14.1M241.3M98.7M60.8M

Cansino Biologics cash flow statement Correlations

0.310.1-0.730.330.56-0.95-0.530.69-0.990.860.28-0.21-0.87-0.43-0.110.010.86
0.31-0.180.29-0.62-0.13-0.120.52-0.16-0.21-0.14-0.25-0.88-0.160.62-0.780.04-0.12
0.1-0.18-0.420.440.45-0.34-0.390.52-0.20.28-0.020.330.34-0.490.590.860.18
-0.730.29-0.42-0.67-0.50.850.96-0.770.82-0.97-0.31-0.370.630.89-0.44-0.23-0.95
0.33-0.620.44-0.670.81-0.54-0.770.85-0.40.640.190.83-0.28-0.890.88-0.010.58
0.56-0.130.45-0.50.81-0.68-0.450.91-0.560.580.160.4-0.35-0.590.560.030.51
-0.95-0.12-0.340.85-0.54-0.680.69-0.830.98-0.94-0.29-0.030.760.64-0.16-0.17-0.92
-0.530.52-0.390.96-0.77-0.450.69-0.730.64-0.88-0.25-0.610.510.97-0.62-0.14-0.87
0.69-0.160.52-0.770.850.91-0.83-0.73-0.720.810.040.45-0.49-0.790.590.120.75
-0.99-0.21-0.20.82-0.4-0.560.980.64-0.72-0.92-0.330.110.840.540.01-0.1-0.92
0.86-0.140.28-0.970.640.58-0.94-0.880.81-0.920.320.25-0.78-0.810.310.080.99
0.28-0.25-0.02-0.310.190.16-0.29-0.250.04-0.330.320.05-0.31-0.270.060.080.33
-0.21-0.880.33-0.370.830.4-0.03-0.610.450.110.250.050.12-0.740.95-0.070.21
-0.87-0.160.340.63-0.28-0.350.760.51-0.490.84-0.78-0.310.120.380.190.43-0.83
-0.430.62-0.490.89-0.89-0.590.640.97-0.790.54-0.81-0.27-0.740.38-0.78-0.16-0.78
-0.11-0.780.59-0.440.880.56-0.16-0.620.590.010.310.060.950.19-0.780.190.23
0.010.040.86-0.23-0.010.03-0.17-0.140.12-0.10.080.08-0.070.43-0.160.190.01
0.86-0.120.18-0.950.580.51-0.92-0.870.75-0.920.990.330.21-0.83-0.780.230.01
Click cells to compare fundamentals

Cansino Biologics Account Relationship Matchups

Cansino Biologics cash flow statement Accounts

201920202021202220232024 (projected)
Change To Inventory(8.1M)(154.6M)(706.4M)(604.0M)(214.4M)(225.1M)
Investments(709.9M)(60.1M)(1.4B)(259.8M)519.9M545.8M
Change In Cash144.6M4.2B1.0B(2.1B)(774.6M)(735.9M)
Net Borrowings(7.3M)(22.5M)969.1M1.2B1.4B1.5B
Free Cash Flow(287.1M)(740.2M)811.4M(3.0B)(1.9B)(1.8B)
Change In Working Capital(12.8M)(100.8M)84.3M(1.5B)(157.0M)(164.8M)
Begin Period Cash Flow57.4M202.0M4.4B5.5B3.0B2.1B
Total Cashflows From Investing Activities(813.7M)(319.7M)(2.6B)(1.2B)(1.1B)(1.2B)
Other Cashflows From Financing Activities(20.9M)(13.6M)598.6M(368K)(423.2K)(402.0K)
Depreciation18.5M24.6M73.4M178.2M269.1M282.5M
Other Non Cash Items(44.5M)(3.1M)(31.6M)(199.5M)(75.8M)(79.6M)
Capital Expenditures116.9M288.3M1.2B1.1B659.7M574.7M
Total Cash From Operating Activities(154.2M)(349.9M)2.0B(1.9B)(916.3M)(870.4M)
Change To Account Receivables(8.6M)(107.8M)(419.9M)(495.8M)(446.2M)(423.9M)
Net Income(156.8M)(396.6M)1.9B(909.4M)(1.4B)(1.4B)
Total Cash From Financing Activities1.1B4.9B1.6B854.2M982.4M1.6B
End Period Cash Flow202.0M4.4B5.5B3.4B2.3B2.5B
Other Cashflows From Investing Activities13.2M28.7M45.8M107.2M123.2M129.4M
Change To Netincome(43.7M)5.4M(66.6M)821.2M944.4M991.7M
Change To Liabilities(2.5M)269.7M1.2B(859.9M)(773.9M)(735.2M)

Currently Active Assets on Macroaxis

Other Information on Investing in Cansino Stock

The Cash Flow Statement is a financial statement that shows how changes in Cansino balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Cansino's non-liquid assets can be easily converted into cash.